MEMohamed Elalfy

Mohamed Elalfy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mohamed Elalfy has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS)

    by Sundas Ejaz Maqsood, John William Posnett, Mohamed Elalfy

    Objective: To evaluate clinical outcomes and resource utilisation of conventional treatment modalities for ocular surface disease involving inflammation and persistent epithelial defect (PED) in an NHS setting, and to compare outcomes with sutureless human amniotic membrane-derived dry matrix (HAMDM) as an alternative therapy. Methods: A retrospective clinical study of 30 patients with PED was conducted across two centres. Treatment duration, healing rates, outpatient (OP) burden, and associated costs were analysed. Outcomes were benchmarked against pooled data from prior studies with HAMDM at the same centres. Results: Conventional management achieved complete healing in 57% of patients, with a mean treatment duration of 176 ± 188 days and 10 OP visits per case. Adjunctive procedures such as tarsorrhaphy (83%) and amniotic membrane transplantation (AMT, 34%) were frequently required. The average total cost per patient was £ 4900 ± £ 3363. In comparison, patients treated with HAMDM achieved higher resolution rates (63%), shorter treatment duration (98 days), fewer OP appointments (8 per case), and a lower treatment cost. Conclusion: PED poses a substantial clinical and economic burden within the NHS. Standard treatments are prolonged and resource-intensive. HAMDM represents a clinically effective and cost-saving alternative, potentially reducing treatment duration, OP burden and overall healthcare costs. Hospital Episode Statistics (HES) data revealed over 138,000 PED-related episodes annually in the NHS, primarily managed in non-surgical settings. These findings therefore support further integration of sutureless amniotic membrane into first-line care strategies for ocular surface disease involving inflammation and PED.


  • Open Access

    Management of Ocular Surface Inflammation with Persistent Epithelial Defects Using a Sutureless Human Amniotic Membrane Dehydrated Matrix: A Prospective Study Utilizing a Digital Ocular Surface Assessment Tool

    by Sundas Ejaz Maqsood, Samer Hamada, Damian Lake, Artemis Matsou, Mohamed Elalfy

    Purpose: To report the outcomes of using a sutureless human amniotic membrane dehydrated matrix (HAMDM) in the management of a range of ocular surface conditions utilizing a digital ocular surface disease assessment tool. Methods: Two UK NHS Trusts — Queen Victoria Hospital Foundation Trust (East Grinstead and Maidstone) and Tunbridge Wells Trust (Kent) — prospectively treated patients with ocular surface disease with sutureless HAMDM. The patient cohort was assessed for resolution of epithelial defects, ocular surface inflammation, and best-corrected visual acuity pre- and posttreatment. Measurements of ocular surface inflammation and epithelial defect size were assessed using AOS digital imaging software, a validated tool for objective grading of bulbar conjunctival redness and measurement of corneal epithelial defects. Results: A total of 47 applications of sutureless HAMDM on 46 eyes of 46 patients (25 male, 21 female, age 9– 94 years) were assessed across various etiologies for an average of 24.0± 14.1 days. Patients with limbal stem-cell deficiency (n=17), persistent epithelial defects (n=16), neurotrophic corneal disease (n=7), filamentary keratitis (n=2), corneal erosion (n=1), corneal thinning (n=1), ocular surface inflammation (n=1), and traumatic corneal laceration (n=1) were included in the study. Across all patents, 63% of eyes showed complete healing of epithelial defects and 32.6% of eyes showed partial resolution. The average rate of healing (wound closure) was 0.36 mm2 per day across the overall patient cohort, and the rate of healing in cases with complete resolution of epithelial defects was 0.41 mm2 per day. Inflammation across all four quadrants of the ocular surface remained stable. Visual acuity across the patient cohort remained stable (61%) and improved in 26% of patients (0.06± 0.51 logMAR). Conclusion: Sutureless HAMDM application can be accomplished in just a few minutes and effectively treat a range of ocular surface disease in a clinical, nonsurgical setting. The AOS imaging software offered a quantitative methodology for measuring epithelial defect size and inflammation state.